Ikena Oncology (NASDAQ:IKNA) Given "Buy" Rating at HC Wainwright

Ikena Oncology (NASDAQ:IKNA - Get Free Report)'s stock had its "buy" rating reaffirmed by equities research analysts at HC Wainwright in a research note issued to investors on Monday,Benzinga reports. They currently have a $4.00 price objective on the stock. HC Wainwright's price objective points to a potential upside of 126.17% from the stock's previous close.

Separately, Wedbush restated a "neutral" rating and issued a $2.00 target price on shares of Ikena Oncology in a research note on Thursday.

Ikena Oncology Stock Up 0.5 %

IKNA traded up $0.01 during trading on Monday, hitting $1.77. The company's stock had a trading volume of 40,954 shares, compared to its average volume of 246,147. The firm has a market capitalization of $85.35 million, a P/E ratio of -1.43 and a beta of 0.48. Ikena Oncology has a twelve month low of $1.22 and a twelve month high of $2.32. The stock's fifty day moving average price is $1.70 and its 200-day moving average price is $1.64.

Ikena Oncology (NASDAQ:IKNA - Get Free Report) last issued its earnings results on Thursday, November 7th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.08. Equities research analysts expect that Ikena Oncology will post -1.03 EPS for the current fiscal year.

Institutional Trading of Ikena Oncology

Hedge funds have recently bought and sold shares of the business. Jacobs Levy Equity Management Inc. grew its holdings in shares of Ikena Oncology by 813.7% during the first quarter. Jacobs Levy Equity Management Inc. now owns 513,440 shares of the company's stock valued at $729,000 after buying an additional 457,245 shares during the last quarter. Sofinnova Investments Inc. increased its holdings in Ikena Oncology by 230.7% during the 2nd quarter. Sofinnova Investments Inc. now owns 382,616 shares of the company's stock worth $631,000 after purchasing an additional 266,904 shares in the last quarter. Acadian Asset Management LLC raised its stake in shares of Ikena Oncology by 1,201.8% in the first quarter. Acadian Asset Management LLC now owns 282,782 shares of the company's stock worth $400,000 after purchasing an additional 261,060 shares during the last quarter. Blue Owl Capital Holdings LP lifted its holdings in shares of Ikena Oncology by 5.1% in the second quarter. Blue Owl Capital Holdings LP now owns 4,091,118 shares of the company's stock valued at $6,750,000 after purchasing an additional 200,000 shares in the last quarter. Finally, BML Capital Management LLC boosted its position in shares of Ikena Oncology by 23.6% during the third quarter. BML Capital Management LLC now owns 723,288 shares of the company's stock valued at $1,251,000 after buying an additional 138,174 shares during the last quarter. Institutional investors and hedge funds own 75.00% of the company's stock.

About Ikena Oncology

Ikena Oncology, Inc operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway.